Renowned experts in virology, immunology, and drug development will help guide INTREPID's efforts to accelerate breakthrough antiviral therapies for emerging viral pandemic agents CAMBRIDGE, Mass. , Oct. 22, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the development of antiviral treatments to help protect the world ahead of future pandemics, today announced the formation of its Scientific Advisory Board (SAB).
Comprising experts in infectious disease research, drug development, innovation and global public health, the SAB will work closely with INTREPID to strengthen its goals to improve pandemic preparedness, and to accelerate the development of potentially life-saving treatments for emerging viral pandemic agents. Specifically, the SAB will provide expert guidance to INTREPID on antiviral research priorities, advising on emerging trends, program strategy, and key scientific issues. It will also interpret landscape data, and help shape long-term strategies to enhance pandemic preparedness.
Ruxandra Draghia-Akli , M.D., Ph.
D. , who was announced as the inaugural chair of the SAB earlier this year, brings to this advisory group a proven track record of driving the discovery, development, and commercialization of pioneering products that advance public health. She is the future Executive Vice President and Head of Research & Development at Novavax where she will be responsible for the company's ex.